From Bench Curiosity to Licensed Product: The History, Science, and Clinical Translation of Messenger RNA Vaccines, with Particular Reference to Seasonal Influenza

Background. Seasonal influenza remains one of the most persistent causes of preventable respiratory morbidity and mortality worldwide, and the egg-propagated inactivated vaccines that have anchored control efforts for eight decades deliver only moderate and highly variable protection. Messenger RNA (mRNA) technology, validated at global scale during the COVID-19 pandemic, has been advanced as a structural remedy for the manufacturing latency and egg-adaptation artifacts that constrain conventional influenza vaccines. In August 2026, the first mRNA influenza vaccine was licensed in the United States, making a historical synthesis of the field both possible and timely. Objective. To trace the intellectual and technical lineage of mRNA vaccines from the discovery of messenger RNA in 1961 to the licensure of mRNA-1010 in 2026, and to appraise the evidence supporting mRNA platforms for seasonal and pandemic influenza. Methods. A structured narrative review was conducted. PubMed, Scopus, Web of Science, ClinicalTrials.gov, and regulatory and sponsor communications were searched from January 1961 through August 2026 using controlled vocabulary and free-text terms for messenger RNA, nucleoside modification, lipid nanoparticle, and influenza vaccine. Sources were selected for historical priority, methodological weight, or regulatory consequence rather than by exhaustive enumeration, and were synthesized chronologically and thematically. Results. Six decades of work resolve into four inflection points. The first was the demonstration between 1978 and 1990 that exogenous mRNA could be delivered into cells and into living animals and translated into functional protein. The second was the recognition in 2005 that substituting modified nucleosides for uridine suppresses innate immune sensing of synthetic mRNA, converting an intolerably inflammatory molecule into a usable therapeutic. The third was the maturation of ionizable lipid nanoparticle delivery between 2010 and 2015. The fourth was the COVID-19 pandemic, which supplied the capital, regulatory precedent, and manufacturing scale that no influenza program could have generated on its own. Influenza-specific mRNA constructs protected animals from lethal challenge in 2012 and entered human trials against H10N8 and H7N9 in 2015. The pivotal Fluent trial, which randomly assigned 40,703 adults aged 50 years or older, reported a relative vaccine efficacy of 26.6 percent for mRNA-1010 against reverse transcriptase polymerase chain reaction-confirmed influenza-like illness compared with a licensed standard-dose comparator, at the cost of substantially higher reactogenicity. The United States Food and Drug Administration licensed the vaccine on August 5, 2026, with full approval for adults aged 50 through 64 years and accelerated approval for adults aged 65 years and older. Conclusions. The mRNA platform has moved from bench curiosity to a licensed influenza product in a single professional generation, and it addresses the specific failure modes of egg-based manufacture rather than merely substituting one antigen delivery system for another. Its near-term value lies less in dramatic efficacy gains than in compressed strain-to-vial timelines, elimination of egg-adaptation artifacts, and pandemic responsiveness. Realizing that value now depends less on immunology than on policy, financing, and public confidence, all of which are presently unsettled in the United States.